Two-thirds price reduction and enhanced capabilities target software development and compliance teams as competition intensifies.

RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited ...

Anthropic has introduced Claude Opus 4.5, its most advanced AI model to date, boasting major gains in coding, tool use, and ...

The average one-year price target for Opus Genetics (NasdaqCM:IRD) has been revised to $7.87 / share. This is an increase of 13.45% from the prior estimate of $6.94 dated November 7, 2025. The price ...

The latest price target for Opus Genetics (NASDAQ:IRD) was reported by Piper Sandler on November 25, 2025. The analyst firm set a price target for $7.00 expecting IRD to rise to within 12 months (a ...

Razer today announced a follow-up to its Opus wireless headset, which launched a little over a year ago. This new over-the-ear headset is simply called the Razer Opus X and, like its predecessor, it ...